60
Participants
Start Date
December 20, 2021
Primary Completion Date
May 31, 2024
Study Completion Date
May 30, 2028
Belantamab mafodotin
"In phase 1:~* Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~* Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
Carfilzomib
"In phase 1:~* Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~* Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~* Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
Dexamethasone
Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients \> 75 years old., Q4W
RECRUITING
Hospital Germans Trias i Pujol (ICO BADALONA), Badalona
NOT_YET_RECRUITING
Hospital Clinic, Barcelona
RECRUITING
ICO Hospitalet, Bellvitge
NOT_YET_RECRUITING
H. Gregorio Marañón, Madrid
NOT_YET_RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
H. Morales Meseguer, Murcia
RECRUITING
HUCA, Oviedo
RECRUITING
H. Son Llatzer, Palma de Mallorca
RECRUITING
Clínica Universidad de Navarra (CUN), Pamplona
RECRUITING
Hospital Universitario de Salamanca, Salamanca
NOT_YET_RECRUITING
H. Universitario de Canarias, Santa Cruz de Tenerife
NOT_YET_RECRUITING
H. Universitario Marqués de Valdecilla, Santander
RECRUITING
Complejo Hospitalario Santiago (CHUS), Santiago de Compostela
RECRUITING
Complejo Hospitalario Virgen del Rocío, Seville
RECRUITING
H.U. La Fe, Valencia
Collaborators (1)
Adknoma Health Research
INDUSTRY
PETHEMA Foundation
OTHER